Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
NCT00446342
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
B-lymphoid Malignancies
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Multiple Myeloma
Interventions
DRUG:
SNS-032 Injection
Sponsor
Sunesis Pharmaceuticals